Evidence map›Paper›PMID 37287989›Full record

ArticleFrontiers in immunology2023

Targeting KRAS

Qi Ai, Fanlu Li, Siyi Zou, Zehui Zhang, Yangbing Jin, Lingxi Jiang, Hao Chen, Xiaxing Deng, Chenghong Peng, Nan Mou and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Shared neoantigens for cancer immunotherapy.Molecular therapy. Oncology · 2025
    Review
  5. Mucosal-associated invariant T-cells in pulmonary pathophysiology.Current opinion in pulmonary medicine · 2025
    Review
  6. Cancer of Unknown Primary Presenting with Chylothorax.Internal medicine (Tokyo, Japan) · 2025
    Article
  7. Review
  8. Article
  9. Colorectal Cancer; Novel Approaches in Chimeric Antigen Receptors (CAR) -T cell.International journal of molecular and cellular medicine · 2025
    Review
  10. Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.International journal of molecular and cellular medicine · 2025
    Review
  11. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
  12. Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Qi AiDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fanlu LiDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Siyi ZouDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zehui ZhangDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yangbing JinDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lingxi JiangDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hao ChenDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaxing DengDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chenghong PengDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nan MouDepartment of Cell Therapy, Shanghai Genbase Biotechnology Co., Ltd, Shanghai, China.
Chenlei WenDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Baiyong ShenDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qian ZhanDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ruijin Hospital · CNShanghai Jiao Tong University · CNState Key Laboratory of Oncogene and Related Genes · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

KRAS mutation is a significant driving factor of tumor, and KRAS

Indexed as

Colorectal NeoplasmsPancreatic NeoplasmsAnimalsAntigens, NeoplasmHumansImmunotherapyMiceMutationProto-Oncogene Proteins p21(ras)Receptors, Antigen, T-CellAntigens, NeoplasmKRAS protein, humanProto-Oncogene Proteins p21(ras)Receptors, Antigen, T-Cellhuman leukocyte antigen-DPB*0301human leukocyte antigen-DPB*1401immunotherapyKRAS G12V mutationsolid tumorT cell receptor-engineered-T cell

Identifiers

PMID37287989
PMCPMC10243368
OpenAlexW4378087098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.